Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics

被引：2

作者：

Shou, Songting ^{[1
]}

Maolan, Ayidana ^{[1
]}

Zhang, Di ^{[1
]}

Jiang, Xiaochen ^{[1
]}

Liu, Fudong ^{[1
]}

Li, Yi ^{[1
]}

Zhang, Xiyuan ^{[1
]}

Geer, En ^{[1
]}

Pu, Zhenqing ^{[1
]}

Hua, Baojin ^{[1
]}

Guo, Qiujun ^{[1
]}

Zhang, Xing ^{[1
]}

Pang, Bo ^{[1
]}

机构：

[1] China Acad Chinese Med Sci, Guanganmen Hosp, Beijing, Peoples R China

来源：

EXPERIMENTAL HEMATOLOGY & ONCOLOGY | 2025年 / 14卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Telomeres; Telomere shortening; Cancer; TERT PROMOTER MUTATIONS; MESSENGER-RNA EXPRESSION; HUMAN BREAST-CANCER; CHRONIC MYELOID-LEUKEMIA; CELL LUNG-CANCER; QUADRUPLEX LIGAND RHPS4; STRUCTURE-BASED DESIGN; DNA-DAMAGE RESPONSES; REVERSE-TRANSCRIPTASE; PHASE-I;

D O I：

10.1186/s40164-025-00597-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Telomeres and telomerase play crucial roles in the initiation and progression of cancer. As biomarkers, they aid in distinguishing benign from malignant tissues. Despite the promising therapeutic potential of targeting telomeres and telomerase for therapy, translating this concept from the laboratory to the clinic remains challenging. Many candidate drugs remain in the experimental stage, with only a few advancing to clinical trials. This review explores the relationship between telomeres, telomerase, and cancer, synthesizing their roles as biomarkers and reviewing the outcomes of completed trials. We propose that changes in telomere length and telomerase activity can be used to stratify cancer stages. Furthermore, we suggest that differential expression of telomere and telomerase components at the subcellular level holds promise as a biomarker. From a therapeutic standpoint, combining telomerase-targeted therapies with drugs that mitigate the adverse effects of telomerase inhibition may offer a viable strategy.

引用

页数：47

共 561 条

[51] Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry [J].

Brümmendorf, TH ;

Holyoake, TL ;

Rufer, N ;

Barnett, MJ ;

Schulzer, M ;

Eaves, CJ ;

Eaves, AC ;

Lansdorp, PM .

BLOOD, 2000, 95 (06) :1883-1890

[52] Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer [J].

Brunsvig, Paal F. ;

Aamdal, Steinar ;

Gjertsen, Marianne K. ;

Kvalheim, Gunnar ;

Markowski-Grimsrud, Carrie J. ;

Sve, Ingunn ;

Dyrhaug, Marianne ;

Trachsel, Sissel ;

Moller, Mona ;

Eriksen, Jon A. ;

Gaudernack, Gustav .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (12) :1553-1564

[53] Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer [J].

Brunsvig, Paal F. ;

Guren, Tormod Kyrre ;

Nyakas, Marta ;

Steinfeldt-Reisse, Claudius H. ;

Rasch, Wenche ;

Kyte, Jon Amund ;

Juul, Hedvig Vidarsdotter ;

Aamdal, Steinar ;

Gaudernack, Gustav ;

Inderberg, Else Marit .

FRONTIERS IN IMMUNOLOGY, 2020, 11

[54] Folate Deficiency Induces Dysfunctional Long and Short Telomeres; Both States Are Associated with Hypomethylation and DNA Damage in Human WIL2-NS Cells [J].

Bull, Caroline F. ;

Mayrhofer, Graham ;

O'Callaghan, Nathan J. ;

Au, Amy Y. ;

Pickett, Hilda A. ;

Low, Grace Kah Mun ;

Zeegers, Dimphy ;

Hande, M. Prakash ;

Fenech, Michael F. .

CANCER PREVENTION RESEARCH, 2014, 7 (01) :128-138

[55] Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma [J].

Buttitta, F ;

Pellegrini, C ;

Marchetti, A ;

Gadducci, A ;

Cosio, S ;

Felicioni, L ;

Barassi, F ;

Salvatore, S ;

Martella, C ;

Coggi, G ;

Bosari, S .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (07) :1320-1325

[56]

Button L, 2019, Poster exhibition Day 1, P2, DOI [10.1136/ijgc-2019-ESGO.126, DOI 10.1136/IJGC-2019-ESGO.126]

[57] A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li-Fraumeni-like families [J].

Calvete, Oriol ;

Martinez, Paula ;

Garcia-Pavia, Pablo ;

Benitez-Buelga, Carlos ;

Paumard-Hernandez, Beatriz ;

Fernandez, Victoria ;

Dominguez, Fernando ;

Salas, Clara ;

Romero-Laorden, Nuria ;

Garcia-Donas, Jesus ;

Carrillo, Jaime ;

Perona, Rosario ;

Carlos Trivino, Juan ;

Andres, Raquel ;

Maria Cano, Juana ;

Rivera, Barbara ;

Alonso-Pulpon, Luis ;

Setien, Fernando ;

Esteller, Manel ;

Rodriguez-Perales, Sandra ;

Bougeard, Gaelle ;

Frebourg, Tierry ;

Urioste, Miguel ;

Blasco, Maria A. ;

Benitez, Javier .

NATURE COMMUNICATIONS, 2015, 6

[58] Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments [J].

Campani, Claudia ;

Imbeaud, Sandrine ;

Couchy, Gabrielle ;

Ziol, Marianne ;

Hirsch, Theo Z. ;

Rebouissou, Sandra ;

Noblet, Benedicte ;

Nahon, Pierre ;

Hormigos, Katia ;

Sidali, Sabrina ;

Seror, Olivier ;

Taly, Valerie ;

Carrie, Nathalie Ganne ;

Laurent-Puig, Pierre ;

Zucman-Rossi, Jessica ;

Nault, Jean-Charles .

GUT, 2024, 73 (11) :1870-1882

[59] Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias [J].

Capraro, Valerie ;

Zane, Linda ;

Poncet, Delphine ;

Perol, David ;

Galia, Perrine ;

Preudhomme, Claude ;

Bonnefoy-Berard, Nathalie ;

Gilson, Eric ;

Thomas, Xavier ;

El-Hamri, Mohamed ;

Chelghoun, Youcef ;

Michallet, Mauricette ;

Wattel, Eric ;

Mortreux, Franck ;

Sibon, David .

EXPERIMENTAL HEMATOLOGY, 2011, 39 (02) :195-202

[60] Hotspot TERT promoter mutations are rare events in testicular germ cell tumors [J].

Carcano, Flavio Mavignier ;

Vidal, Daniel Onofre ;

Lengert, Andre van Helvoort ;

Neto, Cristovam Scapulatempo ;

Queiroz, Luisa ;

Marques, Herlander ;

Baltazar, Fatima ;

da Silva Martinelli, Camila Maria ;

Soares, Paula ;

Albino da Silva, Eduardo Caetano ;

Lopes, Luiz Fernando ;

Reis, Rui Manuel .

TUMOR BIOLOGY, 2016, 37 (04) :4901-4907

← 1 2 3 4 5 6 7 8 9 10 →